Summary

Market Overview
The U.S. Tardive Dyskinesia Treatment market is expected to reach US$ 6417.43 million in 2031, from its recorded value of US$ 3061.64 million in 2023, exhibiting a CAGR of 9.8% during the forecast period.
Tardive dyskinesia (TD) is a neurological disease noted by involuntary, repetitive movements. The disease often results from long-term use of certain medications, particularly antipsychotics, prescribed for psychiatric conditions like schizophrenia and bipolar disorder. 
Symptoms include grimacing, tongue movements, lip smacking, puckering and pursing of the lips, and rapid eye blinking. In some cases, there are also rapid movements of the arms, legs, and trunk.
The major treatment plan involves reducing the dose or discontinuing the medication causing the symptoms, under the direction of a healthcare professional to avoid increasing the underlying condition. 
Alternatives with a lower risk of causing TD, such as atypical antipsychotics like clozapine or quetiapine, may be considered.
Supportive therapies such as physical, speech, and occupational therapy play a crucial role in managing symptoms and enhancing daily functioning. Additionally, lifestyle modifications, including stress management techniques and nutritional support, can help mitigate the impact of TD.
Market Dynamics
Increasing clinical approvals
Increasing clinical approvals significantly drive the tardive dyskinesia (TD) treatment market by enhancing the availability and accessibility of effective treatment options. Regulatory approvals from authoritative bodies like the FDA provide validation of a drug's safety and efficacy, increasing the confidence of healthcare providers in prescribing these medications. This can lead to higher prescription rates and market growth.
For instance, in 2024, the Food and Drug Administration (FDA) approved Austedo XR (deutetrabenazine; Teva Neuroscience, Kansas City, MO) extended-release tablets, a new once-daily formulation of Austedo for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington disease (HD) in adults. Austedo XR is now available in four tablet strengths: 30 mg, 36 mg, 42 mg, and 48 mg. 
The new formulation may help improve treatment adherence and simplify medication management for patients with TD and chorea associated with HD. Through the Teva Shared Solutions program, the company provides support to patients and providers through access, affordability, and adherence strategies.
Additionally, in 2024, the US Food and Drug Administration approved Ingrezza Sprinkle (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD). Ingrezza Sprinkle is a new oral granules formulation of the medication, which is currently approved for the treatment of TD. The new formulation was also approved for the treatment of chorea associated with Huntington's disease in adults.
Ingrezza was the first drug approved to treat TD in 2017. At the time it was granted Fast Track, Priority Review, and Breakthrough Therapy designations.
Market Segment Analysis
The USA Tardive Dyskinesia treatment market is segmented based on Drug, Distribution Channel.
Valbenazine
Valbenazine in the U.S. tardive dyskinesia treatment market was valued at US$ 1799.63 million in 2023 and is estimated to reach US$ 3729.67 million by 2031, growing at a CAGR of 9.7% during the forecast period from 2024-2031. 
Valbenazine selectively inhibits VMAT2, with little to no affinity for VMAT1 or other monoamine receptors. It metabolizes slowly, has less peak-to-trough variations in plasma levels than TBZ, and has a half-life of approximately 20 hours, allowing for a once-daily administration. Genotyping is not required but dosing adjustments are recommended in the presence of CYP 2D6 or CYP 3A4 modulators.
Valbenazine’s mechanism of action is mediated through the reversible inhibition of VMAT2 in the treatment of tardive dyskinesia. VMAT2 is selective to the central nervous system and is responsible for the transport and recycling of neurotransmitters across the synapse. The inhibition of VMAT2 augments neurotransmitter degradation and results in presynaptic neurotransmitter depletion, particularly of dopamine.
Valbenazine has been approved in the USA for the treatment of adults with tardive dyskinesia (tardive dyskinesia) and is at various stages of development in other countries for tardive dyskinesia.
Valbenazine has been approved in the USA since 2017 for the treatment of tardive dyskinesia (tardive dyskinesia), involuntary movements that stem from the use of medications known as neuroleptics or antipsychotics. Antipsychotics are taken by many people worldwide to treat the psychiatric and behavioral symptoms of bipolar disorder, schizophrenia, and other diseases (including Huntington’s disease). 
The advantages of valbenazine include rapid onset of effect within two weeks of treatment initiation. INGREZZA is a prescription medicine used to treat adults with movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia).
Market Segmentation
By Drug
Valbenazine
Deutetrabenazine
Tetrabenazine
Clonazepam
Amantadine
Others
By Distribution channel
Hospital and Speciality Pharmacies
Retail Pharmacies
Others
Major Key players
Teva Pharmaceutical Industries Ltd
Neurocrine Biosciences, Inc. 
Lupin Limited
Accord Healthcare, Inc.
Mitsubishi Corporation
Dr. Reddy’s Laboratories Limited
BIONPHARMA INC. 
Slate Run Pharmaceuticals
Aurobindo Pharma Limited
Apotex Inc.
The U.S. tardive dyskinesia treatment market report would provide access to approx. 42 market data tables, 42 figures, and 123 pages.

ページTOPに戻る

Table of Contents

1. U.S. Tardive Dyskinesia Treatment Market – Methodology and Scope
1.1. Research Methodology
1.2. Scope of the Report
2. U.S. Tardive Dyskinesia Treatment Market – Definition and Overview
3. U.S. Tardive Dyskinesia Treatment Market – Executive Summary
3.1. Market Snippet by Drug
3.2. Market Snippet by Distribution Channel
3.3. Market Snippet by Region
4. U.S. Tardive Dyskinesia Treatment Market – Market Dynamics
4.1. Market Drivers
4.1.1. Increasing clinical approvals
4.1.2. Prolonged use of antipsychotic drugs by patients
4.1.3. An increase in the aging population
4.2. Market Restraints
4.2.1. Side effects associated with the drugs
4.2.2. Lack of awareness about the disorder
4.3. Market Opportunity
4.4. Emerging Countries
4.5. The development of novel therapies
4.6. Impact Analysis
5. U.S. Tardive Dyskinesia Treatment Market – Industry Factors
5.1. Porter’s Five Force Analysis
5.2. Regulatory Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Patent Analysis
5.6. SWOT Analysis
5.7. Unmet Needs
5.8. Epidemiology Analysis
6. U.S. Tardive Dyskinesia Treatment Market – COVID-19
6.1. Analysis of COVID-19 on the Market*
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario After COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. U.S. Tardive Dyskinesia Treatment Market – By Drug
7.1. Introduction
7.1.1. Market Size and Y-o-Y Growth Analysis (%), By Drug
7.1.2. Market Attractiveness Index, By Drug
7.2. Valbenazine*
7.2.1. Introduction
7.2.2. Market Size, 2022-2031 and Y-o-Y Growth (%), 2023-2031
7.3. Tetrabenazine
7.4. Deutetrabenazine
7.5. Amantadine
7.6. Clonazepam
7.7. Others
8. U.S. Tardive Dyskinesia Treatment Market – By Distribution Channel
8.1. Introduction
8.1.1. Market Size and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
9. Hospital and Speciality Pharmacies*
9.1. Introduction
9.2. Market Size, 2022-2031 and Y-o-Y Growth (%), 2023-2031
10. Retail Pharmacies
11. Others
12. U.S. Tardive Dyskinesia Treatment Market – Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. U.S. Tardive Dyskinesia Treatment Market – Company Profiles
13.1. Teva Pharmaceutical Industries Ltd*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Neurocrine Biosciences, Inc.
13.3. Lupin Limited
13.4. Accord Healthcare, Inc.
13.5. Mitsubishi Corporation
13.6. Dr. Reddy’s Laboratories Limited
13.7. BIONPHARMA INC.
13.8. Slate Run Pharmaceuticals
13.9. Aurobindo Pharma Limited
13.10. Apotex Inc.
14. U.S. Tardive Dyskinesia Treatment Market – DataM
14.1. Appendix
14.2. About Us and Services
14.3. Contact Us